Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

PURPOSE: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. PATIENTS AND METHODS: Eighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Nayak, Lakshmi, Molinaro, Annette M., Peters, Katherine, Clarke, Jennifer L., Jordan, Justin T., de Groot, John, Nghiemphu, Leia, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Gaffey, Sarah, Smith, Timothy R., Cote, David J., Severgnini, Mariano, Yearley, Jennifer H., Zhao, Qing, Blumenschein, Wendy M., Duda, Dan G., Muzikansky, Alona, Jain, Rakesh K., Wen, Patrick Y., Reardon, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284901/
https://ncbi.nlm.nih.gov/pubmed/33199490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2500
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados